Search - tctmd.com

Displaying 221 - 240 of 1296

Sort: Relevancy | Date

Presentation TCT 2024

TCT 426: One-Year Clinical Outcome of Prasugrel Monotherapy After PCI for Chronic Coronary Syndrome in Japanese Population

Presenter: KOTARO MIYASHITA

October 29, 2024

Presentation TCT 2024

TCT 832: Impact of Coronary Artery Disease and Revascularization on Clinical and Health Status Outcomes After TAVR: Results From the STS/ACC TVT Registry

Presenter: Yasser Sammour

October 29, 2024

Presentation TCT 2024

TCT 262: Clinical and Hemodynamic Predictors of Stabilization and Associated Complications in Cardiogenic Shock Patients Supported With Impella 5.5

Presenter: Shashank Sinha

October 29, 2024

Presentation TCT 2024

TCT 427: Comparison of Clinical Outcomes Between Second Generation Zotarolimus- Versus Everolimus-Eluting Stents up to 10-Year Follow-up

Presenter: Woo Jin Ahn

October 29, 2024

Presentation TCT 2024

Clinical Phenotypes of TR Patients: Same but Different?

Presenter: Laura Davidson

October 29, 2024

Presentation TCT 2024

Best CLI Medical Therapy Subgroup

Presenter: Matthew Menard

October 29, 2024

Presentation TCT 2024

How Can Clinical Trials Mobilize the Diversity Efforts?

Presenter: Roxana Mehran

October 29, 2024

Presentation TCT 2024

Debate Pro: RDN Could Be Useful for the Majority of Patients with Uncontrolled HTN

Presenter: Raymond Townsend

October 29, 2024

Presentation TCT 2024

Debate Con: RDN Will Ultimately Be a Niche Therapy

Presenter: Andrew Sharp

October 29, 2024

Presentation TCT 2024

Debate Con: Predictors of Efficacy are Sorely Needed in the RDN Space!

Presenter: Eric Secemsky

October 29, 2024

Presentation TCT 2024

Debate Pro: Predictors of Efficacy are Not Needed for Most Patients

Presenter: Michael Weber

October 29, 2024

Presentation TCT 2024

How to Set Up Your RDN Hypertension Program: Team Members and Patient Flow

Presenter: Michael Bloch

October 29, 2024

Presentation TCT 2024

What am I Most Anticipating in Upcoming Clinical Trials?

Presenter: Eric Secemsky

October 29, 2024

Presentation TCT 2024

What Evaluation is Required for Patient Selection for RDN?

Presenter: Naomi Fisher

October 29, 2024

Presentation TCT 2024

Reconciling Device Design and Clinical Need: How to Make TMVr Procedures Scalable and Reproducible?

Presenter: David Meerkin

October 29, 2024

Presentation TCT 2024

Most Important Clinical Trial Endpoints to the PE Clinician in the Trenches

Presenter: Behnood Bikdeli

October 29, 2024

Presentation TCT 2024

Percutaneous Treatment of Tricuspid Regurgitation with the Novel TriFlO® Device: Technology and Clinical Update

Presenter: Gian Paolo Ussia

October 29, 2024

Presentation TCT 2024

TCT 372: Clinical Outcomes Following Sirolimus-Eluting Iron Bioresorbable Scaffold Implantation: One-Year Follow-Up of the Patient-Level Pooled Analysis From the IRONMAN II and III Trials

Presenter: Lei Song

October 29, 2024

Presentation TCT 2024

TCT 370: Clinical Safety and Angiographic Performance of the Fantom Encore Bioresorbable Scaffold: Insights From an Italian Center

Presenter: Francesco Amata

October 29, 2024

Presentation TCT 2024

TCT 115: Association Between Patent Foramen Ovale Morphology and Clinical Outcomes Following Transcatheter Closure

Presenter: Lijie Sun

October 29, 2024

Advertisement

TCT 426: One-Year Clinical Outcome of Prasugrel Monotherapy After PCI for Chronic Coronary Syndrome in Japanese Population

TCT 832: Impact of Coronary Artery Disease and Revascularization on Clinical and Health Status Outcomes After TAVR: Results From the STS/ACC TVT Registry

TCT 262: Clinical and Hemodynamic Predictors of Stabilization and Associated Complications in Cardiogenic Shock Patients Supported With Impella 5.5

TCT 427: Comparison of Clinical Outcomes Between Second Generation Zotarolimus- Versus Everolimus-Eluting Stents up to 10-Year Follow-up

Clinical Phenotypes of TR Patients: Same but Different?

Best CLI Medical Therapy Subgroup

How Can Clinical Trials Mobilize the Diversity Efforts?

Debate Pro: RDN Could Be Useful for the Majority of Patients with Uncontrolled HTN

Debate Con: RDN Will Ultimately Be a Niche Therapy

Debate Con: Predictors of Efficacy are Sorely Needed in the RDN Space!

Debate Pro: Predictors of Efficacy are Not Needed for Most Patients

How to Set Up Your RDN Hypertension Program: Team Members and Patient Flow

What am I Most Anticipating in Upcoming Clinical Trials?

What Evaluation is Required for Patient Selection for RDN?

Reconciling Device Design and Clinical Need: How to Make TMVr Procedures Scalable and Reproducible?

Most Important Clinical Trial Endpoints to the PE Clinician in the Trenches

Percutaneous Treatment of Tricuspid Regurgitation with the Novel TriFlO® Device: Technology and Clinical Update

TCT 372: Clinical Outcomes Following Sirolimus-Eluting Iron Bioresorbable Scaffold Implantation: One-Year Follow-Up of the Patient-Level Pooled Analysis From the IRONMAN II and III Trials

TCT 370: Clinical Safety and Angiographic Performance of the Fantom Encore Bioresorbable Scaffold: Insights From an Italian Center

TCT 115: Association Between Patent Foramen Ovale Morphology and Clinical Outcomes Following Transcatheter Closure

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content